PARIS, France, 18 September 2025 – Boston Scientific Corporation (NYSE: BSX) has received CE mark approval to expand the indication for its current-generation INGEVITY™+ Pacing Leads – thin...
HEMEL HEMPSTEAD, United Kingdom, 24 July, 2025 — Boston Scientific Corporation (NYSE: BSX) today announced CE mark and first procedure in Europe with the Intracept Intraosseous Nerve Ablation...
HEMEL HEMPSTEAD, United Kingdom, 10 July 2025 – Boston Scientific Corporation (NYSE: BSX) today welcomed guidance1 supporting the use of pulsed field ablation (PFA) for the treatment of atrial...
The innovations include advanced pulsed field ablation technologies designed to improve precision, minimize tissue damage, and shorten recovery times. These developments position the company at the forefront of safer, more efficient cardiac rhythm management therapies.
Boston Scientific has inaugurated the Institute for Advancing Science (IAS) in Milan, a new center of excellence equipped with immersive technologies like virtual reality, anatomical models, and simulators, to train healthcare professionals in advanced minimally invasive procedures.
Vincent Sourdaine discusses how precision therapy is transforming Parkinson’s disease and chronic pain treatment and explains how innovations in deep brain stimulation (DBS) and spinal cord stimulation (SCS) enable more personalized, image-guided care for better patient outcomes.
Frédéric Sacher and Laure Champ-Rigot, together with Xavier Bertrand, discuss advances in atrial fibrillation management and stroke prevention. They emphasize the importance of early diagnosis, lifestyle interventions, and innovative ablation techniques such as electroporation to safely restore heart rhythm and reduce the risk of stroke.